RXRX — Recursion Pharmaceuticals, Inc. - Class A Common Stock
Session close: $2.72. Regular-session share volume: 46,905,025. Change from previous close: -3.72%.
Key developments
Morgan Stanley kept a Hold rating on Recursion Pharmaceuticals but cut its price target, signaling a less favorable view of the company's market position and outlook. The update offers a cautious analyst stance rather than a change in conviction, so investors weighing the stock face a tempered valuation signal from a major research firm.
Company news Morgan Stanley Maintains Hold Rating on Recursion Pharmaceuticals, Lowers Price Target
News sources
Company news Morgan Stanley Maintains Hold Rating on Recursion Pharmaceuticals, Lowers Price Target